Cargando…

Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance

The ongoing COVID‐19 pandemic represents an unprecedented global health crisis. Here, we report the identification of a synthetic nanobody (sybody) pair, Sb#15 and Sb#68, that can bind simultaneously to the SARS‐CoV‐2 spike RBD and efficiently neutralize pseudotyped and live viruses by interfering w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Justin D, Scherer, Melanie, Hutter, Cedric A J, Garaeva, Alisa A, Zimmermann, Iwan, Wyss, Marianne, Rheinberger, Jan, Ruedin, Yelena, Earp, Jennifer C, Egloff, Pascal, Sorgenfrei, Michèle, Hürlimann, Lea M, Gonda, Imre, Meier, Gianmarco, Remm, Sille, Thavarasah, Sujani, van Geest, Geert, Bruggmann, Rémy, Zimmer, Gert, Slotboom, Dirk J, Paulino, Cristina, Plattet, Philippe, Seeger, Markus A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982573/ https://www.ncbi.nlm.nih.gov/pubmed/35253970 http://dx.doi.org/10.15252/embr.202154199

Ejemplares similares

Critical discussion on drug efflux in Mycobacterium tuberculosis
por: Remm, Sille, et al.
Publicado: (2021)

Structural basis for triacylglyceride extraction from mycobacterial inner membrane by MFS transporter Rv1410
por: Remm, Sille, et al.
Publicado: (2023)

Increased drug permeability of a stiffened mycobacterial outer membrane in cells lacking MFS transporter Rv1410 and lipoprotein LprG
por: Hohl, Michael, et al.
Publicado: (2019)

Enhancement of Polymeric Immunoglobulin Receptor Transcytosis by Biparatopic VHH
por: Emmerson, Chris D., et al.
Publicado: (2011)

Elevator-type mechanisms of membrane transport
por: Garaeva, Alisa A., et al.
Publicado: (2020)

Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4(+) Cancers
por: Cano-Garrido, Olivia, et al.
Publicado: (2021)

The ABC exporter IrtAB imports and reduces mycobacterial siderophores
por: Arnold, Fabian M., et al.
Publicado: (2020)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
por: Kast, Florian, et al.
Publicado: (2021)

Kinetic mechanism of Na(+)-coupled aspartate transport catalyzed by Glt(Tk)
por: Trinco, Gianluca, et al.
Publicado: (2021)

A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2
por: Garaeva, Alisa A., et al.
Publicado: (2019)

A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
por: Shi, Sally Yu, et al.
Publicado: (2018)

A Tetravalent Biparatopic Antibody Causes Strong HER2 Internalization and Inhibits Cellular Proliferation
por: Benedetti, Filippo, et al.
Publicado: (2021)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

A uniform cloning platform for mycobacterial genetics and protein production
por: Arnold, Fabian M., et al.
Publicado: (2018)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening
por: Bogen, Jan P., et al.
Publicado: (2020)

Biparatopic nanobodies protect mice from lethal challenge with SARS‐CoV‐2 variants of concern
por: Wagner, Teresa R, et al.
Publicado: (2021)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

PnuT uses a facilitated diffusion mechanism for thiamine uptake
por: Jaehme, Michael, et al.
Publicado: (2018)

The extracellular gate shapes the energy profile of an ABC exporter
por: Hutter, Cedric A. J., et al.
Publicado: (2019)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
por: Ugamraj, Harshad S., et al.
Publicado: (2022)

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
por: Mitran, Bogdan, et al.
Publicado: (2018)

Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher
por: Akiba, Hiroki, et al.
Publicado: (2020)

A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms
por: Stefano, James E., et al.
Publicado: (2021)

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models
por: Fan, Jiansheng, et al.
Publicado: (2021)

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
por: DaSilva, John O., et al.
Publicado: (2021)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Canine distemper virus persistence in demyelinating encephalitis by swift intracellular cell-to-cell spread in astrocytes is controlled by the viral attachment protein
por: Wyss-Fluehmann, Gaby, et al.
Publicado: (2010)

Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
por: Fleetwood, Filippa, et al.
Publicado: (2014)

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
por: Godar, Marie, et al.
Publicado: (2016)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy
por: Miao, Xiaoniu, et al.
Publicado: (2020)

Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection
por: Akiba, Hiroki, et al.
Publicado: (2023)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities
por: Liu, Jiayu, et al.
Publicado: (2019)

Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk
por: Tamaskovic, Rastislav, et al.
Publicado: (2016)

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
por: Wang, Yanqun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1rjmr6tchehvpciegumdtf85ur